ONO PHARMA USA, INC. (OPUS) is pursuing the clinical development of new drug candidates and aiming to commercialize in the US. OPUS was established as a US subsidiary of Ono Pharmaceutical Co., Ltd. (ONO) in 1998.
ONO was founded in Osaka, Japan, in 1717. ONO is an R&D-oriented pharmaceutical company committed to discovering and developing “first-in-class” medicines, like Opdivo® (nivolumab), an anti-PD-1 antibody drug, focusing on the oncology, immunology, neurology and specialty research.